Immunome, Inc.
IMNMHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Immunome, Inc. focuses on Biotechnology services and products. Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United. The $2.12B market capitalization puts IMNM squarely in mid-cap range for its industry. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Market Cap
$2.12B
Beta
2.56
P/E (TTM)
—
P/E (Fwd)
-7.32
EPS (TTM)
$-2.48
EPS (Fwd)
$-2.46
ROE
-64.0%
ROA
-37.8%
Cash
$520.0M
Total Debt
$4.7M
Free CF
-$143.7M
52W Change
14.7%
Annual Financials
Cash vs Debt
Where IMNM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IMNM finished 25.66% below its 150-day moving average ($22.56) and 25.76% below its 200-day moving average ($22.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMNM overbought or oversold?
At the October 20, 2026 close, IMNM's RSI(14) was 16.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $520.0M in cash and $4.7M in debt, IMNM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$143.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -64.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, IMNM tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing IMNM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.